Sign in
Enrolling by invitationNo phase

Registry Following Patients Treated With Embolization for Thyroid Disease

Collects data on quality of life after embolization of enlarged thyroid tissue in adults.

Key facts

Who runs it
Sarasota Memorial Health Care System
Where
Atlanta, Jacksonville, New Orleans, and Sarasota, United StatesSee the 4 sites
Trial code
Registry title
Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry
Status
Enrolling by invitation
People taking part
100 people, planned
Started
1 Apr 2025
Expected to end
1 Apr 2028
Type of study
Observational
Treatments tested
  • Data Collection
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The registry collects data from adults who had thyroid artery embolization with the TriNav Infusion System for an overactive thyroid, a thyroid goiter, or thyroid nodules.

Age
18 to 89 years
Sex
All sexes
Disease stage
Overactive thyroid with a toxic multinodular goiter or a toxic nodule > 20 ml; or a non-functioning goiter or nodule causing pressure symptoms; or a benign-looking nodule (Bethesda 2-3 twice, benign molecular profile).
Earlier treatment
Must have had thyroid embolization (PED-TAE) with the TriNav Infusion System. Cannot have had prior thyroid thermal ablation.
Biomarker or test result
Bethesda category 2-3 on 2 separate fine-needle biopsies with a benign molecular profile, for the nodule group.

Main reasons for not taking part

  • Kidney problems (renal insufficiency)
  • Cannot tolerate angiography, including pregnancy or severe contrast allergy
  • Bethesda 4-6 on needle biopsy
  • Graves' disease or Hashimoto's thyroiditis
  • No inferior thyroid artery, for example a bovine arch

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adults, 18 years and or older and 89 years or younger
  • Having undergone PED-TAE using the TriNav Infusion System
  • Meeting one of the following criteria:; Documented subclinical and or clinical hyperthyroidism in the presence of a toxic multinodular goiter or a toxic nodule > 20 ml; Patients' ineligible or refusing surgery, radio-iodine therapy or percutaneous ablation; Non-functioning multinodular goiters or nodule causing compressive symptoms including but not limited to neck pain, dysphagia, stridor, exercise induced dyspnea and/or pressure symptoms; Bethesda category 2-3 (benign, or atypia or follicular lesion of undetermined significance) on 2 separate fine-needle aspiration biopsy (FNAB) results with a benign molecular profile with patient declining surgical resection

Who cannot take part

  • Prior thyroid thermal ablation
  • Renal insufficiency
  • Unable to tolerate angiography including pregnancy and severe allergy to contrast media
  • Bethesda 4-6 on FNAB (suspicious for follicular neoplasm, suspicious for malignancy, or malignant)
  • Graves' disease or inflammatory thyroiditis (Hashimoto's) or other condition with the presence of an extensive collateral network as demonstrated or initial angiography
  • <18 years old or >89 years old
  • Presence of a bovine arch or any other anatomical variant with no inferior thyroid artery present

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 89 years old?

Where in United States

  • Emory University School of MedicineAtlanta, United StatesEnrolling by invitation
  • Mayo ClinicJacksonville, United StatesEnrolling by invitation
  • Tulane University School of MedicineNew Orleans, United StatesEnrolling by invitation
  • Sarasota Memorial Health Care SystemSarasota, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

Multi-center registry study to evaluate disease-related quality of life outcomes of thyroid embolization via pressure-enabled delivery (PED-TAE). Additional technical success data on parenchymal volume reduction, thyroid function tests changes and post-procedural complications will be recorded. Data will be collected for patients who have undergone PED-TAE using the TriNav Infusion System at participating sites. The registry study will include up to 10 sites, with Sarasota Memorial Health Care System acting as the lead site responsible for maintaining and monitoring the study database.

The group in the trial

  • Patients who have undergone PED-TAE using the TriNav Infusion System at participating study sites.

    Subjects with planned PED-TAE delivered via TriNav will receive their treatment following routine standard of care procedures. Post-procedural data obtained by a patient chart review will be collected in a study database. No additional study-specific interventions or visits outside of the routine clinical treatment will be performed.

    Treatment: Data Collection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry
Plain-language title
Registry Following Patients Treated With Embolization for Thyroid DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06868459, who can take part
Record updated
30 September 2026